Agreement for liquidity providing terminated
Uppsala, October 27, 2020. The agreement with Mangold Fondkommission to act as the liquidity provider for Dicot AB's share has been terminated. The assignment will end on October 29, 2020. The share has a good spread and the liquidity providing is no longer needed. No new liquidity guarantor replaces the previous commitment as the need no longer exists.
If you have additional questions, please contact:
Göran Beijer, CEO
Tel: +46 70-663 60 09
E-mail: [email protected]
Dicot AB in brief
Dicot is a pharmaceutical company focused on drug discovery and the development of novel lifestyle drugs to enrich patients' lives. The Company develops and manufactures medicines for the treatment of erectile dysfunction and premature ejaculation. The Company's lead drug candidate, Libiguin®, for the treatment of sexual dysfunctions, is in a stage of pre-clinical development. Dicot is listed on the Spotlight Stock Market and has approximately 1,800 shareholders. For more information see www.dicot.se.
Om Dicot Pharma
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
